[{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Endocrinology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Bank Degroof Petercam","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Bank Degroof Petercam"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Kreos Capital","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Kreos Capital"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Termination","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ VIB"}]
Find Clinical Drug Pipeline Developments & Deals by Oxurion
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
